Cochrane · systematic review · CD011271
Melatonin and agomelatine for preventing seasonal affective disorder
Nussbaumer‐Streit, B, Greenblatt, A, Kaminski‐Hartenthaler, A, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
2
Included studies
NR
No studies 2 · 33.3%Ungraded 0 · 0%Very low 4 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Agomelatine compared to placebo for preventing seasonal affective disorder (SAD)
Population: adults with a history of SAD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of SAD (modified ITT) Agomelatine vs placebo | RR 0.83 [0.51, 1.34] | 1 study · 199 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Number of persons with at least one adverse event within a year Agomelatine vs placebo | RR 1.06 [0.84, 1.34] | 1 study · 225 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Severity of depression (SIGH‐SAD score) at the end of the study Agomelatine vs placebo | no estimate extracted | 1 study · 199 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Quality of life Agomelatine vs placebo | no estimate extracted | NR | No studies |
Quality of interpersonal and social functioning Agomelatine vs placebo | no estimate extracted | NR | No studies |
Number of persons with at least one severe adverse event within a year Agomelatine vs placebo | RR 0.76 [0.17, 3.3] | 1 study · 225 participants | Very low Downgraded: risk of bias, imprecision, indirectness |